Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve Regurgitation
Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve Regurgitation
The purpose of this study is to test the safety and device performance of the Mitralign
 system ("MPAS") to treat functional mitral valve regurgitation.
The ALIGN study is a single arm, prospective study. The objective of the study is to
 investigate the safety and performance of a catheter-based plication device intended to
 reduce the circumference of the dilated mitral valve. The study will enroll up to 50 subjects
 from up to 5 sites (Paraguay, Columbia, Dominican Republic, Brazil, and India) who will be
 followed for 36 months post index procedure. Enrollment is defined at the time the study
 device is inserted into the body and patients will be followed at 30 days, and Months 6, 12,
 24 and 36 post index procedure.
Inclusion Criteria:

 -  NYHA II-IV

 -  Structurally normal mitral valve

 -  At least Grade 2 mitral regurgitation

 -  Left ventricular ejection fraction not less than 20% and not greater than 45%

 -  Left ventricular end diastolic diameter not less than 5.0 cm and not greater than 7.5
 cm

 Exclusion Criteria:

 -  Pregnant or lactating female

 -  Mitral stenosis

 -  Mod/severe aortic stenosis or regurgitation

 -  Mod/severe tricuspid stenosis or regurgitation

 -  Endocarditis

 -  Previous mitral valve repair or MV replacement

 -  Bioprosthetic or mechanical aortic valve

 -  Known unstable angina or MI within 30 days prior to procedure

 -  CVA within past 6 months

 -  Known contraindications to blood transfusion, contrast dye, DAPT